Recent Event Highlights: Novartis erzielt im dritten Quartal eine hervorragende Performance - Swiss-press.com (Pressemitteilung), Novartis profits climb as new treatments shine - Pharma Times, Novartis affiche une nette croissance des résultats sur neuf mois - Romandie.com, Novartis delivers excellent performance in third quarter: recently launched ... - MarketWatch, Drug company to repay state Medicaid - The Rolla Daily News, Tennessee to receive more than $4 million in drug company settlement - The Tennessean, and 12 more...
Created by dipity on Jul 25, 2009
Last updated: 11/03/10 at 08:38 PM
Tekturna has no followers yet. Be the first one to follow.
Novartis Q310 Results - Outperforming RivalsPharmaceuticals & Healthcare Insight (registration)... Exjade (deferasirox), Reclast/Aclasta (zoledronic acid), Tekturna/Rasilez (aliskiren), Tasigna (nilotinib), Afinitor (everolimus), Onbrez Breezhaler, ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEmpmXyRKjhjuD7UwRlekXemOlulg&url=http://www.pharmaceuticalsinsight.com/file/93546/novartis-q310-results---outperforming-rivals.html
IMS心脑血管类药物2009-2018年预测报告（四）搜狐 (博客)阿利吉仑在美国的名称是Tekturna，在英国、德国和加拿大的名称为Rasilez。2008年年底，该产品在墨西哥和西班牙推出。2008年2月在日本作为高血压新药提交申请。 ...
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNF88Gp9DXGIheCFz903oi70wasO2g&url=http://zhishuirenshan.blog.sohu.com/161538651.html
Novartis erzielt im dritten Quartal eine hervorragende PerformanceSwiss-press.com (Pressemitteilung)Tekturna (+42% kWk) setzte sein starkes Wachstum fort, und auch Exforge (+33% kWk) erzielte in allen Märkten weltweit kräftige Zuwächse. ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGRA3bj5m7D43ZDgsmPm6yymeJ3fQ&url=http://swiss-press.com/newsflashartikel.cfm?key%3D931588
Novartis Ergebnisse über Erwartungensharewise.com... 8% vorhergesehen gewesen, Diovan sei besser als erwartet gewesen, aber Gleevec, Zometa, Exjade, Exelon und Tekturna hätten unter den Prognosen gelegen. ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEM9GrLVWmvizAn0zepZx25p0yLDg&url=http://www.de.sharewise.com/aktien/CH0012005267-novartis-nam-sf-0-50/analyse/2123540
Novartis profits climb as new treatments shinePharma TimesThe antihypertensive Tekturna/Rasilez (aliskiren) leapt 36% to $113 million. Other highlights were the sales of Lucentis (ranibizumab) for the treatment of ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFz8snnqYTIKunOcc99trYCq_3x4w&url=http://www.pharmatimes.com/Article/10-10-21/Novartis_profits_climb_as_new_treatments_shine.aspx
Novartis affiche une nette croissance des résultats sur neuf moisRomandie.comY figurent notamment Exforge et Tekturna (hypertension), Tasigna (leucémie) et Lucentis (maladie des yeux). La division Vaccins et Diagnostic a poussé ses ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFx1Vx0baYzMi2c-u034HvKP_SH1w&url=http://www.romandie.com/infos/ats/display.asp?page%3D20101021121841520172019048082_brf034.xml%26associate%3Dphf9283
Novartis delivers excellent performance in third quarter: recently launched ...MarketWatchTekturna (+42% cc) continued to grow strongly and Exforge (+33% cc) also had strong growth in all global markets. Galvus (+114% cc) sales grew strongly in ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEuU4p2En9EzfcvrVMxoFUyoU76ag&url=http://www.marketwatch.com/story/novartis-delivers-excellent-performance-in-third-quarter-recently-launched-products-generate-20-of-sales-gilenya-approved-alcon-consolidated-2010-10-21?reflink%3DMW_news_stmp
Drug company to repay state MedicaidThe Rolla Daily NewsThe allegations involve the Novartis drugs Trileptal, Diovan, Zelnorm, Sandostatin, Tekturna, and Exforge. Novartis will pay the states and the federal ...
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGmMq0pn5iJlMP0Urg58-Uo9OBV9g&url=http://www.therolladailynews.com/newsnow/x1404213843/Drug-company-to-repay-state-Medicaid
Tennessee to receive more than $4 million in drug company settlementThe Tennessean... million settlement with Novartis Pharmaceutical Corporation in New Jersey over the drugs Trileptal, Diovan, Zelnorm, Sandostatin, Exforge and Tekturna. ...Tennessee gets $4.1 million in Novartis settlementMemphis Commercial AppealTennessee To Receive $4123148 From Drug CompanyThe Chattanooganall 7 news articles »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNG2N4CBvNcwdX65u0DIsJYOiR2WSA&url=http://www.tennessean.com/article/20101012/NEWS03/101012041/Tennessee-to-receive-more-than-4-million-in-drug-company-settlement
My Portfolio: Sipp reasons to be more cheeryFinancial TimesThe pill combines the only approved direct renin inhibitor Tekturna (alikiren) with amlodipine, a widely used calcium channel blocker. ...
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEfgTSBK2QV3ceLe69xwdAJc3mFbw&url=http://www.ft.com/cms/s/641cecfc-c283-11df-956e-00144feab49a.html
Novartis Gets FDA Approval for Tekturna-Amlodipine CombinationFDA news (subscription)The FDA has approved Novartis' Tekamlo, a pill containing its renin inhibitor Tekturna (aliskiren) and amlodipine (Pfizer's Norvasc), as initial therapy for ...
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNF7_wpeUZ2yAK_3KbNT51qVv_IpfQ&url=http://fdanews.com/newsletter/article?issueId%3D13995%26articleId%3D129849
诺华高血压治疗新药Tekamlo即将进入美国销售生物谷诺华新型高血压治疗药Tekamlo已通过FDA的上市批准，该药为复方制剂，同时含有直接作用型肾素抑制剂Tekturna和氨氯地平（amlodipine）两种成分。 ...
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHKQ75hdMqG5Nx112W0G2nXFa3YVw&url=http://www.bioon.com/industry/enterprisenews/453413.shtml
Star Global Tribune (blog)FDA Approves TekamloDrug Discovery & DevelopmentThe Tekturna component targets the activity of the renin angiotensin aldosterone system (RAAS), an important regulator of blood pressure. ...FDA gives nod to Novartis' hypertension drugCardiovascular BusinessMaybe Not a Blockbuster, But We'll Take ItMotley FoolNovartis' Tekamlo Gains FDA Nod - Analyst BlogBenzingaall 12 news articles »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFoFi2CBg_GHfSIkJyqp9jtGSc74Q&url=http://www.dddmag.com/news-FDA-Approves-Tekamlo-83010.aspx
santé logHYPERTENSION : La FDA approuve TEKAMLO®, le comprimé de Novartissanté log... le seul l'inhibiteur de la rénine autorisé, Rasilez/Tekturna® (aliskiren) avec l'inhibiteur largement utilisé des canaux calciques, l'amlodipine. ...
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNG-0vlA4UIXLLtHIOiUaFCX9_M4iw&url=http://www.santelog.com/modules/connaissances/actualite-sante-hypertension-la-fda-approuve-tekamloreg-le-comprimeacute-de-novartis_3835.htm
TopNews United Kingdom (blog)FDA approves Novartis' combo pill TeklamoFierceBiotechThe FDA has approved Teklamo, a high blood pressure medication that combines Tekturna with the calcium channel blocker amlodipine. ...Novel Combo Pill for Hypertension ApprovedMedPage TodayNovartis receives FDA approval of Tekamlo(TM), a single-pill combination of ...MarketWatch (press release)Novartis Pharma Tekamlo gets FDA approvalPharmaceutical Business ReviewdBTechno -International Business Times -Reutersall 72 news articles »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNF7E_6YciHPRTReQ1cQRlebbOuriA&url=http://www.fiercebiotech.com/story/fda-approves-novartis-teklamo/2010-08-27
Novartis erhält Zulassungen für Tekamlo in USA und Tasigna in der Schweiz (AF)swissinfo.chDas Produkte kombiniere die beiden Wirkstoffe Tekturna (Aliskiren) und Amlodipine in einer Pille. Tekamlo sei für Personen vorgesehen, ...Novartis erhält Zulassungen für Medikamente in USA und Schweizboerse.de (Pressemitteilung)all 17 news articles »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFUC34jDHKMrCu0JT27o-LCBGtb7Q&url=http://www.swissinfo.ch/ger/news/newsticker/wirtschaft/Novartis_erhaelt_Zulassungen_fuer_Tekamlo_in_USA_und_Tasigna_in_der_Schweiz_(AF).html?cid%3D27249744
Novartis: la FDA homologue Tekamlo (un seul comprimé) pour l'hypertension (dév.)Romandie.comPour le Tekturna et ses combinaisons, Vontobel table sur un chiffre d'affaires de 3 mrd USD. Il sera important de connaître les résultats des grandes séries ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHA6PvBx_FzzsAvrbDEBqLus6iPfA&url=http://www.romandie.com/infos/awp/display.asp?id%3D201008271010050AWPCH.asp
FDA puts brakes on Roche, ImmunoGen cancer drugReutersNovartis was given a boost on Friday after it got US backing for a new treatment of high blood pressure, broadening the use of Tekturna, the successor to ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGPuwA7eoAx662Bv6FWGSO5fXnB3A&url=http://www.reuters.com/article/idUSLDE67Q03620100827
European Factors -- Shares seen lower; Bernanke eyedReutersVX) received US approval for a new treatment of high blood pressure, broadening the use of Tekturna, the successor to the group's best-selling drug, Diovan. ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEJw5cKOskpoJCprXPuJNQCpkomxA&url=http://www.reuters.com/article/idUSLDE67313N20100827
Shares of Novartis AG (NYSE:NVS) are trading 1.6% higher to $54.31 Tuesday following a Reuters report that the Swiss drug maker will plead guilty to violating US Laws relating to off-label marketing and promotion of an epilepsy treatment and pay a $185 million fine. "In the fourth quarter of 2009, Novartis increased provisions relating to the EDPA's Trileptal investigations by $318 million," it said in a statement. In addition, Novartis Pharmaceuticals is cooperating with a US Attorney's Office for the Eastern District of Pennsylvania (EDPA) investigation into potential off-label marketing and promotion as well as payments made to healthcare providers in connection with the following products: Diovan, Exforge, Sandostatin, Tekturna and Zelnorm. "Novartis is unable to assess with reasonable certainty the outcome of the investigation related to these five products or the amounts, which could be material, that it might be required to pay to resolve this investigation," the company said.
Excerpt
...Speaking last week on a conference call for the firm’s second-quarter results, Novartis pharma chief Joe Jimenez said that Tekturna may generate sales of up to $300 million this year. Alnylam deal extended Meantime, Alnylam Pharmaceuticals has revealed that...
Source Info
PharmaTimes
Related Topics
http://www.pharmatimes.com/WorldNews/article.aspx?id=16267&src=WorldNewsRSS
, MD, one of the authors of JNC-VII, talks about latest updates in hypertension and diabetes as well as his new handbook titled Contemporary Diagnosis and Management of Hypertension and Diabetes ... ARB ACE DRI Renin Inhibition American College of Cardiology Heart Association Society hypertension Hypertension Diovan Exforge Azor Coreg CR bystolic nebivolol Diabetes januvia byetta George Bakris aliskiren Tekturna Cozaar avapro metabolic syndrome pharmaceutical representative PhRMA guidelines code ...
Excerpt
...Vasella has said that Novartis, the Swiss drugs company, has no problem with its drugs pipeline but that the market debut of Tekturna, the novel blood-pressure treatment designed to replace the group’s Diovan blockbuster, has prompted differing opinions –...
Source Info
Financial Times
http://www.ft.com/cms/s/68bfa802-3bd6-11dd-9cb2-0000779fd2ac.html
Excerpt
...Considerations: IMPORTANT WARNING: If you get pregnant, stop taking Tekturna and call your doctor right away. Tekturna may harm an unborn baby, causing injury and even death. If you plan to become pregnant, talk to your doctor about other treatment options...
Source Info
PR Newswire
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/06-04-2008/0004826729&EDATE=
Excerpt
...associated with high blood pressure and Tekturna offers an exciting new therapeutic option for treating hypertension. Tekturna is manufactured by Novartis Pharmaceuticals which will conduct a large outcome trial in order to evaluate the long-term effects of...
Source Info
News-Medical.net
Related Topics
http://www.news-medical.net/?id=22436
Excerpt
...to deliver to market. March 6 2007: 7:31 AM EST BASEL, Switzerland (Reuters) -- Novartis AG's pill for high blood pressure, Tekturna, won U.S. regulatory approval, calming investor fears about the firm's ability to get new drugs to market and boosting its...
Source Info
CNN/Money
Related Topics
http://money.cnn.com/rssclick/2007/03/06/news/international/bc.novartis.tekturna.reut/index.htm?section=money_latest
Excerpt
...would never reach the $3 billion a year predicted by some analysts. Potential blockbusters Galvus, plus blood pressure treatments Tekturna and Exforge, are seen as key near-term sales drivers - though they are also the firm's major risks in case of any delays...
Source Info
CNN/Money
http://money.cnn.com/rssclick/2006/11/28/news/companies/novartis.reut/index.htm?section=money_news_international
Update Sources